Innocan Pharma Corporation announced the publication of a research article titled "Liposomal-synthetic-cannabidiol: preliminary translational evidence of efficacy, tolerability and pharmacokinetics following repeated subcutaneous injections in two goats" in the peer reviewed esteemed journal Frontiers in Pharmacology. Two goats suffering from chronic and disabling painful condition were treated with subcutaneous Synthetic Liposomal Cannabidiol (LPT-CBD, 5 mg/kg) injections every six weeks for 10 months. Efficacy was assessed by the caregivers via quality of life (QoL) weekly scoring, and adverse effects were monitored.
Key findings include: Repeated LPT-CBD injections (7 injections per goat) maintained sustained CBD plasma concentrations consistent with a slow-release pharmacokinetic profile. F favorable drug tolerability was observed throughout the study with no recorded adverse events. In contrast to repeated oral CBD consumption in humans, this study showed that repeated LPT-CBD injections did not elevate liver enzymes-markers typically associated with liver injury (2).
Repeated administration of LPT-CBD resulted in sustained pain relief, improved mobility, and enhanced quality of life, consistently maintained during the study period (10 months). The results of this study offer clinically translatable information. LPT-CBD injections every 6 weeks are practical, have shown no adverse effects, and provide long-term CBD plasma concentrations.
Additionally, LPT-CBD demonstrated remarkable efficacy trends in pain control and wellbeing improvement for several weeks and can potentially provide similar results in people.
